Whole Blood Coagulation Time
"Whole Blood Coagulation Time" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The time required by whole blood to produce a visible clot.
| Descriptor ID |
D014914
|
| MeSH Number(s) |
E01.370.225.625.115.950 E05.200.625.115.950 G09.188.960
|
| Concept/Terms |
Whole Blood Coagulation Time- Whole Blood Coagulation Time
- Blood Coagulation Time, Whole
- Coagulation Time, Whole Blood
- Activated Coagulation Time, Whole Blood
|
Below are MeSH descriptors whose meaning is more general than "Whole Blood Coagulation Time".
Below are MeSH descriptors whose meaning is more specific than "Whole Blood Coagulation Time".
This graph shows the total number of publications written about "Whole Blood Coagulation Time" by people in this website by year, and whether "Whole Blood Coagulation Time" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Whole Blood Coagulation Time" by people in Profiles.
-
Morita Y, Strauss E, Tanaka KA. Low ACT After High-Dose Heparin: Is Hemodilution Best Option to Pass by Syclla and Charybdis? A A Pract. 2019 12 15; 13(12):479.
-
Ulmer FF, Baulig W, B?ttex D, Spielmann N, B?rki C, Weiss M. Measurement of activated coagulation time in children: evaluation of the blood-saving kaolin i-STAT activated coagulation time technique in pediatric cardiac anesthesia. J Cardiothorac Vasc Anesth. 2011 Jun; 25(3):395-401.
-
Marmur JD, Bullock-Palmer RP, Poludasu S, Cavusoglu E. Avoiding intelligence failures in the cardiac catheterization laboratory: Strategies for the safe and rational use of dalteparin or enoxaparin during percutaneous coronary intervention. J Invasive Cardiol. 2009 Dec; 21(12):653-64.
-
Nankervis CA, Preston TJ, Dysart KC, Wilkinson WD, Chicoine LG, Welty SE, Nelin LD. Assessing heparin dosing in neonates on venoarterial extracorporeal membrane oxygenation. ASAIO J. 2007 Jan-Feb; 53(1):111-4.
-
Faraday N, Becker DM, Yanek LR, Herrera-Galeano JE, Segal JB, Moy TF, Bray PF, Becker LC. Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population. Am J Cardiol. 2006 Sep 15; 98(6):774-9.
-
Meneveau NF, Klugherz BD, Chaqour B, Anand V, Tomaszewski JE, Joullié MM, Macarak E, Golden M, Weisz PB, Wilensky RL. Beta-cyclodextrin tetradecasulfate, a novel cyclic oligosaccharide, inhibits thrombus and neointimal formation after coronary vascular injury. Coron Artery Dis. 2002 May; 13(3):189-97.